Amid global anxiety over the novel coronavirus, a newly issued warning letter by the Food and Drug Administration serves as a reminder that quality manufacturing needs to remain a priority.

Consider the March 17 missive sent to Windlas Healthcare, which formulates finished medicines for some of the world’s largest drug makers. The company committed several serious infractions that alarmed the agency following an August 2019 inspection of a manufacturing facility in northern India.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Made even more disturbing with the announcement that FDA is postponing all foreign establishment inspections until further notice.

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy